ALKS vs AXSM
ALKS: Alkermes is a neuroscience-focused biopharmaceutical company developing and commercializing therapeutic treatments for complex neurological and psychiatric disorders. AXSM: A biopharmaceutical company developing and commercializing innovative therapies for central nervous system disorders.
Side-by-side fundamentals
| Metric | ALKS | AXSM | Edge |
|---|---|---|---|
| Price as of 2026-08-10 close | $49.40 | $220.89 | |
| Market cap as of 2026-08-11 | $8.3B | $11.4B | |
| P/E as of 2026-08-11 | 124.75 | n/a | |
| PEG as of 2026-08-11 | -19.70 | 1.94 | ALKS lower |
| Net margin as of 2026-08-11 | +4.0% | -26.6% | ALKS higher |
| Gross margin as of 2026-08-11 | +84.6% | +92.6% | AXSM higher |
| Operating margin as of 2026-08-11 | +7.0% | -25.9% | ALKS higher |
| ROE as of 2026-08-11 | +3.7% | -260.0% | ALKS higher |
| ROA as of 2026-08-11 | +2.0% | -27.8% | ALKS higher |
| Debt / equity as of 2026-08-11 | 0.83 | 3.61 | ALKS lower |
| Revenue growth (YoY) as of 2026-08-11 | +10.8% | +63.9% | AXSM higher |
| Revenue CAGR (3y) SEC XBRL | +9.9% | +133.7% | AXSM higher |
| Beta as of 2026-08-11 | 0.25 | 0.86 | |
| 1-year return as of 2026-08-10 close | +84.9% | +110.8% | AXSM higher |
Fundamentals: market data, as of 2026-08-11. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-10.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.